# TITLE PAGE

# Gastric coagulation and postprandial amino acid absorption of milk is affected by mineral composition: a randomized crossover trial

Elise J.M. van Eijnatten, MSc, Julia J.M. Roelofs, MSc, Guido Camps, PhD, Thom

Huppertz, PhD, Tim T. Lambers, PhD, Paul A.M. Smeets, PhD

Author affiliations:

- Division of Human Nutrition and Health, Wageningen University, Stippeneng 4,
   6708 PB Wageningen, the Netherlands (EE, JR, GC, PS)
- Food Quality and Design group, Wageningen University, Bornse Weilanden 9,
   6708 WG Wageningen, the Netherlands (TH)
- FrieslandCampina, Stationsplein 4, 3818 LE Amersfoort, the Netherlands (TT, TH)

**Disclaimers: none** 

Corresponding Author: Name: Elise van Eijnatten Mailing address: Stippeneng 4, 6708 WE Wageningen Telephone number: 0031642565543 E-mail address: elise.vaneijnatten@wur.nl

All sources of financial support: FrieslandCampina

## It is made available under a CC-BY-ND 4.0 International license .

Short running head: Digestion and absorption of coagulated casein

# List of abbreviations:

- 95% CI 95% confidence interval
- BMI Body mass index
- GE Gastric emptying
- GE-t50 Gastric emptying half time
- CM Casein mineralization
- MD Mean difference
- MRI Magnetic resonance imaging

Clinical trial registry number: NL8959 (Dutch Trial Registry) accessible through

https://onderzoekmetmensen.nl/en/trial/20073.

Pubmed indexing:

van Eijnatten EJM

Roelofs JJM

Camps G

Lambers TT

Huppertz T

Smeets PAM

Word count: 4282

Number of figures: 6

Number of tables: 0

Supplementary data submitted: yes

The data described in the manuscript, code book, and analytic code will be made

available upon request.

It is made available under a CC-BY-ND 4.0 International license .

1

# 2 ABSTRACT

Background: *In vitro* studies suggest that casein coagulation of milk is influenced by its
 mineral composition, and may therefore affect the dynamics of protein digestion, gastric
 emptying and appearance of amino acids (AA) in the blood, but this remains to be
 confirmed *in vivo*.

Objective: This study aimed to compare gastrointestinal digestion between two milks
 with the same total calcium content but different casein mineralization (CM).

Design: Fifteen males (age 30.9±13.8 y, BMI 22.5±2.2 kg/m2) participated in this 9 randomized cross-over study with two treatments. Participants underwent gastric 10 magnetic resonance imaging (MRI) scans at baseline and every 10 min up to 90 min 11 after consumption of 600 ml milk with low or high CM. Blood samples were taken at 12 baseline and up to 5 hours postprandially. Primary outcomes were postprandial plasma 13 AA concentrations and gastric emptying rate. Secondary outcomes were postprandial 14 glucose and insulin levels, gastric coagulation as estimated by image texture metrics, 15 and appetite ratings. 16

**Results:** Gastric content volume over time was similar for both treatments. However, gastric content image analysis suggested that the liquid fraction emptied quicker in the high CM milk, while the coagulum emptied slower. Relative to high CM, low CM showed earlier appearance of AAs that are more dominant in casein, such as proline (MD 4.18 µmol/L, 95%CI [2.38-5.98], p<0.001), while there was no difference in appearance of AAs that are more dominant in whey protein, such as leucine. The image texture metrics

## It is made available under a CC-BY-ND 4.0 International license .

- homogeneity and busyness differed significantly between treatments (MD 0.007, 95%CI
- 24 [0.001, 0.012], p=0.022; MD 0.005, 95%CI [0.001, 0.010], p=0.012) likely because of a
- reduced coagulation in the low CM milk.
- 26 **Conclusions:** Mineral composition of milk can influence postprandial serum AA kinetics,
- 27 likely due to differences in coagulation dynamics.
- 28
- 29 Keywords: milk, digestion, casein, micellar calcium, gastric emptying, amino acids,
- 30 glucose, insulin

#### 5

# 31 INTRODUCTION

Protein is an essential macronutrient for many functions in the human body<sup>1, 2</sup>. 32 Consuming sufficient protein can be a challenge. Therefore, optimal digestion and 33 absorption of the consumed protein support bioavailability of amino acids (AA)<sup>3, 4</sup>. A 34 common source of protein is bovine milk<sup>5</sup>, which generally contains about 3.5% protein, 35 of which caseins represent around 80% and whey proteins around 20%<sup>6</sup>. While whey 36 protein remains soluble, casein coagulates in the stomach when casein micelles are 37 destabilized by pepsin proteolysis<sup>7</sup>. This leads to the formation of curds containing 38 protein and fat globules that impact overall digestion kinetics, such as protein digestion 39 and absorption<sup>8</sup>. 40

## 41

Previous studies, predominantly in vitro, suggest that casein coagulation is affected by 42 several factors, including processing-induced protein modifications, overall product 43 composition, including mineral composition, and variations in gastric acidification and 44 protease secretion<sup>9-12</sup>. It is important to fully understand the effect of processing-induced 45 protein modifications of milk on coagulation since coagulation could influence the rate at 46 47 which protein empties from the stomach and thereby affect protein digestion and absorption kinetics<sup>13</sup>. Gastric emptying (GE) is the rate-limiting step in the delivery of 48 nutrients to the small intestine for further breakdown and absorption<sup>14</sup>. GE rate of liquids 49 is mainly driven by energy density and viscosity<sup>15</sup>. However, compared to whey proteins, 50 the coagulated casein fraction of milk empties later, because the stomach only empties 51 particles sized below 1–2 mm<sup>14, 16</sup>. Accordingly, whey proteins, which remain soluble, 52 have a higher GE rate than caseins<sup>17, 18</sup>. Processing of milk alters its functional 53

6

properties including casein and its coagulation<sup>19</sup>, which could influence GE and related 54 digestion kinetics. This is supported by recent in vivo work showing that the processing 55 of casein and the resulting alterations in the product matrix can have a strong effect on 56 postprandial AA responses. For instance, cross-linked sodium caseinate was more 57 rapidly digested than micellar casein and calcium caseinate and upon the ingestion of 58 dairy products containing 25 g protein, and a higher increase in EAA concentrations in 59 blood was observed after consumption of yoghurt, compared to milk and cheese<sup>20, 21</sup>. 60 The rate at which AA are absorbed greatly affects their availability for muscle protein 61 synthesis<sup>22</sup>. A faster release of milk proteins results in a more prominent muscle 62 synthetic response, whereas a slower release of protein from the stomach results in a 63 better net postprandial protein utilization<sup>7</sup>. Thus, the degree of casein coagulation in the 64 stomach could affect the dynamics of gastric protein digestion, stomach emptying, and 65 subsequent intestinal digestion and absorption of AA. 66

67

Both the physical (e.g., compactness, hardness and elasticity, size of fat globules) and 68 the chemical parameters (e.g., protein/lipid ratio, P/Ca ratio) can influence the milk 69 matrix and could therefore affect the bioavailability of AA<sup>3</sup>. In vitro studies indicate that 70 casein coagulation is affected by mineral composition<sup>23</sup> since caseins form casein 71 micelles with calcium, phosphate, and magnesium<sup>24</sup>. Partial decalcification of casein 72 micelles results in looser-formed gastric clots and greater proteolysis<sup>25</sup>. Casein 73 mineralization (CM) also affected the coagulation of milk proteins in a model infant 74 formula<sup>26</sup>. The effect of CM on coagulation was followed up by a study on the 75 coagulating behavior of bovine casein micelles under infant, adult, and elderly conditions 76

7

where gastric coagula became looser and the formation of free amino groups and small 77 peptides increased with an increasing level of decalcification<sup>27</sup>. However, thus far, only 78 in vitro or indirect (by measuring AA kinetics) in vivo studies have been done, in which 79 other product differences than only mineralization were studied. MRI could be a helpful 80 tool in assessing casein coagulation. Currently, the main use of MRI in gastric research 81 is measuring GE<sup>28, 29</sup>. But MRI can also be used to visualize intragastric processes, such 82 as changes from liquid to solid state, gastric sieving and phase separation<sup>30, 31</sup>, which is 83 an advantage over ultrasound or tracer-methodology. Since gastric protein coagulation 84 involves a change from a liquid to a semi-solid state, MRI could potentially be used to 85 quantify the degree of coagulation. So far, gastric coagulation has only been visually 86 assessed using MRI<sup>32</sup>, however image texture analysis may provide a more objective 87 and accurate quantification<sup>29</sup>. 88

89

This study aimed to compare gastrointestinal digestion (coagulation, GE, and postprandial AA dynamics) between skimmed bovine milks with the same total calcium content but a different degree of CM. We hypothesized that gastric protein coagulation would be more prominent in milk with higher CM and consequently delay gastric protein emptying, serum AA appearance, and related glycemic responses.

8

# 95 PARTICIPANTS AND METHODS

# 96 Design

This study was a randomized, single-blinded, crossover study with two treatments.
Washout was at least one week, and sessions were a maximum two months apart.
Primary outcomes were postprandial plasma amino-acid concentrations and gastric
emptying rate. Secondary outcomes were postprandial glucose and insulin levels,
gastric coagulation, and other product instabilities if visible and appetite ratings obtained
after each MRI measurement. The results are presented in the order of (I) coagulation,
(II) gastric emptying, (III) AAs, (IV) insulin / glucose and (V) appetite ratings.

104

# 105 **Participants**

Healthy males, aged 18-55 years, BMI 18.5-25.0 kg/m<sup>2</sup>, were recruited from the 106 Wageningen area from December 2020 to March 2021. Exclusion criteria were bovine 107 milk allergy, lactose intolerance (either self-reported or diagnosed), gastric disorders or 108 regular gastric complaints, such as heartburn, use of proton pump inhibitors or other 109 medication which alters the normal functioning of the stomach, recreational use of 110 drugs, within one month prior to the pre-study screenings day, alcohol consumption of 111 more than 14 standard units/week, being vegan, smoking, or having a contraindication 112 to MRI. Because there are sex differences in gastrointestinal function<sup>33, 34</sup>, males were 113 chosen as the study group. The sample size was calculated for the first primary 114 outcome, the postprandial AA profile, based on the expected difference in peak serum 115 AA concentration. We estimated the peak difference to be 0.4 pmol/ml, with an SD of 116

#### It is made available under a CC-BY-ND 4.0 International license .

9

0.3 pmol/ml based on an earlier study performed with differently treated dairy products 117 that are comparable to these study products<sup>21</sup>. The power was set to 0.9. This resulted 118 in an estimated sample size of n=14. However, to account for a possible smaller 119 difference, it was decided to include 15 participants. Fifteen males (age: 30.9±13.8 120 vears; BMI:  $22.5\pm2.2$  kg/m<sup>2</sup>) completed this study. See the flow diagram in 121 Supplementary figure 1. The study was conducted according to the principles of the 122 Declaration of Helsinki (October 2013) and registered with the Dutch Trial Registry 123 number NL8959 accessible under through 124 https://trialsearch.who.int/Trial2.aspx?TrialID=NL8959. All participants provided written 125 informed consent. 126

127

# 128 Study procedures

On the day before each test session, participants consumed a standardized 500-kcal 129 rice dinner, which they could finish or eat less if they preferred. Drinks were free of 130 choice. After this, participants fasted for at least 12 hours until the test session the 131 following morning. Drinking water was allowed up to 1.5 hours before the session. 132 Participants arrived at the hospital Gelderse Vallei, Ede, The Netherlands, at 8 or 10 AM 133 and were measured at the same time on both study days. Figure 1 shows an overview 134 of a test session. Upon arrival, an intravenous (IV) cannula was placed in an antecubital 135 vein. Baseline measurements consisted of appetite ratings, an abdominal MRI scan, and 136 a blood sample. Subsequently, participants were instructed to consume 600 ml of a test 137 product within five minutes, but all finished between one and four minutes. Gastric MRI 138 scans were performed at baseline and every ten minutes, starting at T = 10 min up to 90 139

#### It is made available under a CC-BY-ND 4.0 International license .

10

minutes after the start of consumption. During the MRI session, participants verbally rated subjective appetite: hunger, thirst, fullness, desire to eat, and prospective consumption on a scale from 0 (not at all) to 100 (most imaginable) at each time point<sup>35</sup>. Blood samples were drawn at baseline and at T = 15, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, and 300 min.

145

The test products were two skimmed milks with different micellar mineral composition, 146 provided by FrieslandCampina. The low CM product was skimmed milk with 20 mM 147 added trisodium citrate, resulting in a degree of CM of 4.3 mmol protein-associated 148 Ca/10 g casein, determined as described previously<sup>36</sup>. Adding citrate alters the micellar 149 calcium content and thereby the casein micelle integrity<sup>37</sup>. To maintain a similar 150 buffering capacity in the high CM product, disodium hydrogen phosphate was added to 151 skimmed milk at a level of 20 mM, resulting in a degree of CM of 8.9 mmol protein-152 associated Ca/10 g casein. Solutions were made at the same time in the afternoon 153 preceding the test day and were slowly mixed with a magnetic stirrer at 4° C overnight to 154 create an equilibrium of micellar and non-micellar calcium. The difference in gastric 155 protein coagulation was determined by wet weight measurements of the coagulates 156 during *in vitro* gastric digestion (Supplementary figure 2). The nutritional value of both 157 test products per 600 ml prepared product was 831 kJ/195 kcal, 0 g fat, 27 g 158 carbohydrate, 21 g protein and 762 mg calcium. Participants were randomly allocated by 159 block randomization using randomizer.org to receive either the low CM or the high CM 160 milk first. The milks were similar in appearance and taste and participants were blinded 161 to the milk they received. 162

163

# 164 **MRI**

Participants were scanned in a supine position with the use of a Philips Ingenia Elition X 165 3.0T MRI scanner. A T<sub>2</sub>-weighted ~20-s 2-D Turbo Spin Echo sequence (37 4-mm 166 slices, 2 mm gap, 1 x 1 mm in-plane resolution, TR = 550 ms, TE = 80 ms, flip angle: 90 167 degrees) was used with breath-hold command on expiration to fixate the position of the 168 diaphragm and the stomach. The software Medical Imaging Processing And 169 Visualization (MIPAV, version 11.0.3) was used to manually delineate gastric content on 170 every slice<sup>38</sup>. Volumes on each time point were calculated by multiplying the surface 171 area of gastric content per slice with slice thickness, including gap distance, and 172 summed over the total number of slices showing gastric content. To assess changes in 173 gastric coagulation, image texture analysis of the stomach content was performed using 174 the software LIFEx (version 7.2.0, Institut national de la santé et de la recherche 175 médicale. France)<sup>39</sup>. Homogeneity, coarseness, contrast, and busyness were 176 calculated. These image metrics provide information on the spatial patterns of voxel 177 intensity<sup>40</sup>. The Gray-Level Co-occurrence Matrix (GLCM) method was used for 178 homogeneity (degree of similarity between voxels) and Neighborhood Gray-level 179 Difference Matrix (NGLDM) difference of grey-levels between one voxel and its 26 180 neighbors in 8 dimensions was used for contrast (local variations), coarseness (spatial 181 rate of change in intensity) and busyness (spatial frequency of changes in intensity). The 182 number of grey levels for texture metric calculation was set at 64, intensity rescaling at 183 relative (ROI: min/max), and dimension processing at 2D. On each postprandial time 184 point, texture metrics were calculated per slice for the stomach content. Subsequently, a 185

12

weighted average texture metric was calculated based on the gastric content volume in 186 each slice such that slices with little stomach content contributed less to the average 187 than those with more stomach content. To quantify the (relative) volume of liquid and 188 semi-solid stomach contents the number of lighter (more liquid), intermediate and darker 189 (semi-solid) voxels was calculated by determining intensity thresholds with the use of 190 Otsu's method<sup>41</sup> in Matlab (version R2023a, multitresh function) an approach previously 191 used on *in vitro* MRI images of milk digestion<sup>42</sup>. The number of intermediate and darker 192 voxels were summed and interpreted as reflecting coagulation. This was done because 193 visual inspection of the thresholding results showed that in these images a separation in 194 two categories was not accurate. In the context of this study, changes in image texture 195 metrics were interpreted as reflecting changes in the degree of coagulation. An example 196 of stomachs with and without coagulation and their corresponding image texture 197 measures can be found in Supplementary figure 3. 198

199

# 200 Blood collection and analysis

Blood samples (10 ml) were drawn from the IV cannula into sodium-fluoride, serum-, and lithium-heparin tubes. After collection, sodium-fluoride and lithium-heparin tubes were centrifuged at 1000 x *g* for 10 min at 22°C within 30 min, to obtain blood plasma. To obtain blood serum, serum tubes were first allowed to clot for 30 min before being centrifuged at the same conditions as the other tubes. Following centrifugation, serum aliquots of 500  $\mu$ l and 250  $\mu$ l were pipetted in 5 ml tubes and stored at -80°C until they were analyzed in bulk.

13

208

Analysis and quantification of serum AA concentrations were done using liquid 209 chromatography mass spectrometry (LC-MS) triple quad, with an internal standard and 210 13C reference mixture<sup>43</sup>. For determination of the glucose concentrations, plasma 211 samples were processed using an Atellica CH Glucose Hexokinase 3 (GluH 3) assay 212 kit and guantified using an Atellica CH analyzer (Siemens Healthineers, The 213 Netherlands). The lower limit of detection was 0.2 mmol/l and intra-assay CVs were at 214 most 4.5%. Serum insulin was processed and its concentrations were quantified using 215 an enzymatic immunoassay kit (ELISA, Mercodia AB, Sweden) with a limit of detection 216 of 0.008 mmol/l and intra assay CVs of at most 6.8%. 217

218

## 219 Statistical analysis

To estimate gastric emptying half time (GE-t50), a commonly used summary measure 220 for each scan session, a curve was fitted according to an established linear-exponential 221 model as developed based on earlier models of GE to the data of gastric volume over 222 time using R statistical software<sup>16, 44-46</sup>. This method works well for gastric content that 223 increases due to gastric excretion in the early phase (lag phase) and afterward empties 224 almost linearly. Further analyses were performed in SPSS (version 22, IBM, Armonk, 225 USA). GE-t50 was compared between low and high CM milk with a paired t-test. The 226 serum AA were categorized into three groups: branched-chain amino acids (BCAA), 227 essential amino acids (EAA), and non-essential amino acids (NEAA) and their content 228 was summed. Overall blood parameters, gastric volume, image texture metrics, and 229

14

appetite ratings were tested using linear mixed models with treatment, time, and 230 treatment\*time as fixed factors and baseline values as covariate. An extra analysis on 231 the first 90 min of the blood parameters was conducted since this is when differences in 232 gastric coagulation were expected. Proline, an AA more dominant in casein, and 233 leucine, an AA more dominant in a whey protein, were used as a showcase since the 234 expected difference in AA kinetics would be driven by differing casein coagulation and 235 not whey. After this, we estimated the contribution of casein and whey proteins by 236 determining the casein/whey AA ratio 'Q' of serum AA from the concentrations of 237 proline, phenylalanine, aspartic acid, asparagine, and alanine according to the method 238 of Jacobs et al. <sup>47</sup> described for food products. Normality was confirmed by quantile-239 quantile plots of the residuals, except for insulin, which was log-transformed to meet 240 normality. Missing data was handled using a Maximum Likelihood estimation. The 241 significance threshold was set at p = 0.05. Data are expressed as mean  $\pm$  SD unless 242 stated otherwise. 243

15

# 244 **RESULTS**

# 245 **Coagulation metrics**

Qualitatively, coagulation was visible on the MRI images for both high and low CM milk 246 (Supplementary figure 4). The image texture metrics homogeneity and busyness were 247 higher for high CM milk (MD 0.007, 95% CI [0.001, 0.012], p=0.022 and MD 0.005, 95% 248 CI [0.001, 0.010], p=0.012, respectively). Coarseness (MD 0.001, 95% CI [-0.001, 249 0.002], p=0.512),) and contrast (MD -0.086, 95% CI [-0.203, 0.031], p=0.149) were not 250 significantly different. There were no time\*treatment interaction effects. Figure 2 shows 251 homogeneity over time as an example. Figures of busyness, coarseness, and contrast 252 can be found in Supplementary figure 5. 253

254

# 255 Gastric emptying

There was no significant difference in gastric volume over time between treatments (MD 3.8, 95% CI -8.2, 15.8, p = 0.53). This is in line with the GE-t50: low CM milk 45.6  $\pm$  7.8 min and high CM milk 46.6  $\pm$  8.7 min (MD 1.0, 95% CI [-1.9, 4.0], p = 0.46) (**Figure 3**). There was a higher proportion of liquid over time between treatments in the low CM condition (MD 2.2 %, 95% CI [0.30, 4.1], p = 0.023) (**Supplementary figure 6**).

261

# 262 Amino acids

The total EAA postprandial response over time was similar for low and high CM milk (MD -2.6  $\mu$ mol/L, 95% CI [-8.5, 3.2], p = 0.379, time p < 0.001, time \* treatment p =

270	CM milk. Figures of separate AAs can be found in Supplementary figures 7, 8 and 9.
269	treatment $p = 0.135$ ) driven by t = 60 min, $p = 0.001$ ) was significantly higher for the low
268	BCAA valine (MTD -1.784, 95% CI [-3.531, -0.038], $p = 0.045$ , time $p < 0.001$ , time*
267	time*treatment $p = 0.095$ ), driven by time point T = 60 min, p<0.001 (Figure 4). The
266	for the interaction of time and treatment (MD $\mu$ mol/L -4.3, 95% CI [-7.4, -1.1], p = 0.008,
265	0.374) and total NEAA response over time was higher for the low CM milk with a trend

271

Analysis of the first 90 min, when the effect of a reduced casein coagulation is to be expected, showed higher total serum AA for low CM for both EAA (MD 45.3  $\mu$ mol/L, 95% CI [14.9 – 75.6], p=0.004 and T = 60 p = 0.001) and NEAA (MD 56.7  $\mu$ mol/L, 95% CI [24.7 – 88.6], p<0.001, T = 60, p = 0.005).

276

Relative to high CM milk, low CM milk showed earlier appearance of AAs more dominant in casein, such as proline (MD 4.18  $\mu$ mol/L, 95 % CI [2.38-5.98], treatment p < 0.001), while there was no difference in AA appearance of AAs more dominant in whey protein, such as leucine (MD 0.563  $\mu$ mol/L, 95 % CI [-0.99-2.12], treatment p = 0.477). In line with these observations, analysis of the estimated serum casein/whey AA ratio showed a difference between the treatments (MD 0.056, 95% CI [0.022-0.091], treatment p = 0.002, T = 30 min p = 0.015) (**Figure 5**).

284

# 285 **Glucose and insulin**

17

Glucose over time did not differ between treatments (MD -0.047 mmol/L, 95% CI [-286 0.373, 0.278], p = 0.915) and there was no time\*treatment interaction (p = 0.99). The 287 insulin response over time was significantly lower for the high CM milk (MD 0.072 288 (mIU/L), 95% CI [0.019, 0.125], p = 0.008). Post-hoc t-tests showed that this is driven by 289 time points T = 30 (MD 8.4, 95% CI [2.8, 14.0], p = 0.004) and T = 45 min (MD 6.9, 95%) 290 CI [1.3, 12.5], p = 0.016). There was no time\*treatment interaction (p = 0.38). Graphs of 291 both insulin and glucose can be found in Figure 6. 292

293

296

#### **Appetite ratings** 294

Hunger (MD 2.7, 95% CI [-0.418, 5.87], p = 0.089), fullness (MD 0.97, 95% CI [-2.06, 295 3.99}, p = 0.53), desire to eat (MD 0.26, 95% CI [-2.80, 3.32], p = 0.87), prospective

consumption (MD -1.22, 95% CI [-3.99, 1.56], p = 0.388), thirst (MD -2.56, 95% CI [-297

5.96, 0.84], p = 0.139 did not differ between treatments (**Supplementary figure 10**). 298

There were no interaction effects for any rating. 299

300

#### Time effects 301

There was a significant time effect for all mixed model analyses of AA. GE. glucose, and 302 insulin, coagulation metrics and appetite ratings (all p < 0.001). 303

18

# 304 **DISCUSSION**

To the best of our knowledge this is the first *in vivo* study that directly evaluated the 305 effect of milk mineral composition on gastric casein coagulation, GE, AA and glycemic 306 responses. Among the image texture metrics used to estimate the degree of 307 coagulation, homogeneity and busyness were higher for the high CM milk compared to 308 the low CM milk. As expected, the rate of gastric emptying, as measured by gastric 309 volume curves over time and GE-t50, was similar for the two milks since they only 310 differed in mineral composition. The serum AAs that are more dominant in casein, such 311 as proline, and estimated serum casein/whey AA ratio were significantly higher for the 312 low CM milk, predominantly driven by time point T = 60 min. There was no difference in 313 314 glucose response. The insulin response was significantly lower for the high CM milk: driven by time points T = 30 and T = 45 min which were in line with differences in 315 316 postprandial BCAA valine.

317

We used image texture metrics as an objective measure to quantify the degree of 318 coagulation. A difference in homogeneity and busyness implies a difference in 319 coagulation between the high CM milk and the low CM milk. This is in line with previous 320 in vitro work applying model IF formula and simulated infant digestion<sup>26</sup> and our in vitro 321 digestions of the test products under simulated adult conditions (Supplementary figure 322 323 2). Both in vitro studies showed a substantial difference in coagula between low and high CM samples, in line with an overall reduced casein coagulation and formation of a 324 more open structured curd for the low CM milk. However, these measures should be 325 further validated, since such image analyses to quantify the degree of structure 326

19

formation have been used in other areas<sup>48, 49</sup>, but are novel for characterizing gastric 327 protein coagulation<sup>29</sup>. In the current study, homogeneity and busyness were both higher. 328 which seems contradictive: a higher homogeneity may imply a lower degree of 329 coagulation, while higher busyness may imply a higher degree of coagulation. What 330 should be considered is that higher homogeneity could not only reflect a homogenous 331 liquid, but also result from the presence of large coagulates. Another aspect to consider 332 is that not only the size, but also the structure is an important characteristic of coagula. 333 For instance, we know that some coagulates are firm and have a dense structure, and 334 greater weight than less dense coagulates with approximately the same volume<sup>50</sup>. 335 Indeed, lower CM resulted in smaller and softer curd particles in vitro, likely because of 336 higher concentration of non-micellar casein, which hinder enzymatic coagulation of 337 casein micelles<sup>26</sup>. MRI is sensitive to water content, so could provide information on 338 water contained in the coagulum and therefore its density. It should be noted that MRI 339 image texture parameters are affected by the resolution of the input images and could 340 detect differences in image intensity patterns that are not clearly distinguishable by 341 viewing the MRI images. This needs further validation by concomitant analysis of MRI 342 images and coagulates that differ in size and density. Other MRI techniques are being 343 developed that can provide molecular-level information such as measurement of the 344 magnetization transfer ratio and relaxation rates<sup>42, 51, 52</sup>. These measurements require 345 additional MRI spectra to be recorded, but could be used in follow-up research to 346 examine more subtle differences in protein coagulation in vivo. 347

348

20

The differences in coagulation between the two milks did not affect gastric emptying 349 rate: the GE curves were similar for both milks. However, the threshold analysis showed 350 that most of the liquid fraction emptied sooner than the semi-solid (coagulated) fraction. 351 It is known from in vitro and animal in vivo models that complete breakdown and 352 subsequent GE of the coagulated casein fraction can take longer than complete 353 emptying of the liquid fraction<sup>4, 7, 13, 17, 26, 53</sup>. This is likely a consequence of the increased 354 particle size exceeding the maximum size that can pass the pyloric filter<sup>14</sup> and may be 355 physiologically important to provide a sustained release of amino acids to the neonate. 356 Accordingly, whey proteins, which remain soluble, have a higher GE rate than caseins<sup>18</sup>. 357 Studies comparing whey and casein show a difference in overall GE as assessed with 358 MRI and ultrasonography<sup>17, 54, 55</sup>. However, one study with preterm infants using whey 359 and casein-dominant formulas found similar GE<sup>56</sup>. Likely, overall GE rates vary between 360 studies likely as a consequence of the different formulations used. 361

362

363 Gastric casein coagulation differences can likely explain the observed difference in overall postprandial AA profiles. Looking at the first 90 min, when the effect of 364 differences in casein coagulation could be expected, both EAA and NEAA responses 365 were significantly lower for high CM milk. This is in line with our hypothesis and is 366 probably caused by the delay in emptying of the coagulated casein fraction. Indeed, 367 proline, an AA more dominant in casein AA was significantly different between the 368 treatments, whereas leucine, an AA that is more dominant in whey protein, was not, 369 further illustrating that micellar calcium only affects the coagulation and digestion of the 370 casein fraction. This is strengthened by the findings of differences in the estimated 371

## It is made available under a CC-BY-ND 4.0 International license .

21

372 serum whey/casein AA ratio. A reduced casein mineralization can also explain recent *in* 373 *vivo* observations where overall digestion of mineral-depleted milk protein concentrate
 374 was faster than that of a regular CM milk<sup>57</sup>.

375

No differences in glucose responses were observed, which is not surprising since carbohydrate (lactose) concentration was the same for both treatments. The lower insulin levels observed in response to high CM milk are likely due to the difference in BCAAs and/or other insulinotropic AAs present in the milk. In this study the BCAA valine was significantly higher for the low CM milk. The BCAA have the potential to influence insulin responses<sup>58, 59</sup>.

382

In conclusion, milks with different mineral compositions show different coagulating 383 properties, as measured with higher serum AA in low CM milk, confirming in vitro results. 384 Coagulation differences were further supported by MRI image analyses. Although the 385 different coagulation properties did not influence overall GE the liquid fraction emptied 386 quicker, while the coagulum persisted. This is in line with the difference in AA kinetics 387 388 where the effects were predominantly driven by AAs more dominant in casein. The results suggest that the mineral composition of milk can influence gastric coagulation 389 and protein digestion. This knowledge may help to determine the optimal processing of 390 391 dairy products and their effect on digestion and health. Future studies should focus on improving measurements of the degree of coagulation and coagulum structure with MRI 392 and examining the physiological relevance of the observed differences. 393

# 394 ACKNOWLEDGEMENTS

TL, and PS designed the research; EE and JR conducted the research. TL and TH 395 provided essential materials. EE analyzed the data and drafted the paper. EE, JR, GC, 396 TL, TH, and PS revised the manuscript critically for important intellectual content. PS 397 had primary responsibility for the final content. All authors read and approved the final 398 manuscript. This study was funded by FrieslandCampina and TL and TH are employed 399 by FrieslandCampina. All other authors declare no further conflict of interest. We thank 400 Lisa van den Berg, Caya Lindner, Jinke Oosterhof, and Jesper Rietmeijer for assisting 401 with data collection, Jacques Vervoort and Sebas Wesseling for their work on the AA 402 analysis and Christophe Nioche for his support with the LIFEx software. The use of the 403 3T MRI was made possible by WUR Shared Research Facilities. 404

# REFERENCES

- 1. H. J. Coelho-Junior, B. Rodrigues, M. Uchida and E. Marzetti, *Nutrients*, 2018, **10**.
- 2. D. H. Sullivan, S. Sun and R. C. Walls, *JAMA*, 1999, **281**, 2013-2019.
- 3. A. Fardet, D. Dupont, L.-E. Rioux and S. L. Turgeon, *Critical Reviews in Food Science and Nutrition*, 2019, **59**, 1987-2010.
- 4. S. Mahé, N. Roos, R. Benamouzig, L. Davin, C. Luengo, L. Gagnon, N. Gaussergès, J. Rautureau and D. Tomé, *The American Journal of Clinical Nutrition*, 1996, **63**, 546-552.
- 5. K. N. van Rossum, C Wilson, M Ocké, *EFSA supporting publication*, 2018, DOI: 10.2903/sp.efsa.2018.EN-1488, 25 pp.
- 6. A. Haug, A. T. Høstmark and O. M. Harstad, *Lipids in Health and Disease*, 2007, **6**, 25.
- 7. Y. Boirie, M. Dangin, P. Gachon, M.-P. Vasson, J.-L. Maubois and B. Beaufrère, *Proceedings of the National Academy of Sciences*, 1997, **94**, 14930-14935.
- 8. A. Ye, W. Liu, J. Cui, X. Kong, D. Roy, Y. Kong, J. Han and H. Singh, Food Chemistry, 2019, **286**, 216-225.
- 9. A.-I. Mulet-Cabero, A. Torcello-Gómez, S. Saha, A. R. Mackie, P. J. Wilde and A. Brodkorb, *Food Chemistry*, 2020, **319**, 126514.
- M. Corredig and E. Salvatore, in Advanced Dairy Chemistry: Volume 1B: Proteins: Applied Aspects, eds. P. L. H. McSweeney and J. A. O'Mahony, Springer New York, New York, NY, 2016, DOI: 10.1007/978-1-4939-2800-2\_11, pp. 287-307.
- 11. A. M. H. Horstman and T. Huppertz, *Critical Reviews in Food Science and Nutrition*, 2022, DOI: 10.1080/10408398.2022.2078782, 1-16.
- 12. T. Huppertz and L. W. Chia, *International Dairy Journal*, 2021, **113**, 104882.
- 13. D. Roy, P. J. Moughan, A. Ye, S. M. Hodgkinson, N. Stroebinger, S. Li, A. C. Dave, C. A. Montoya and H. Singh, *Journal of Dairy Science*, 2022, DOI: <u>https://doi.org/10.3168/jds.2021-21388</u>.
- 14. F. Kong and R. P. Singh, *Journal of food science*, 2008, **73**, R67-80.
- 15. Camps, M. Mars, C. de Graaf and P. A. M. Smeets, *The American Journal of Clinical Nutrition*, 2016, **104**, 73-80.
- 16. J. D. Elashoff, T. J. Reedy and J. H. Meyer, *Gastroenterology*, 1982, **83**, 1306-1312.
- 17. Y. Sakata, T. Yago, S. Mori, N. Seto, Y. Matsunaga, H. Nakamura, T. Tominaga, K. Miyaji and Y. Takeda, J Nutr, 2022, **152**, 2367-2375.
- 18. J. M. Aguilera, Critical Reviews in Food Science and Nutrition, 2019, **59**, 3612-3629.
- 19. D. G. Dalgleish and M. Corredig, Annu Rev Food Sci Technol, 2012, 3, 449-467.
- 20. J. Trommelen, M. E. G. Weijzen, J. van Kranenburg, R. A. Ganzevles, M. Beelen, L. B. Verdijk and L. J. C. van Loon, *Nutrients*, 2020, **12**.
- 21. A. M. H. Horstman, R. A. Ganzevles, U. Kudla, A. F. M. Kardinaal, J. J. G. C. van den Borne and T. Huppertz, *International Dairy Journal*, 2021, **113**, 104890.
- 22. M. Lacroix, C. Bos, J. Léonil, G. Airinei, C. Luengo, S. Daré, R. Benamouzig, H. Fouillet, J. Fauquant, D. Tomé and C. Gaudichon, *Am J Clin Nutr*, 2006, **84**, 1070-1079.
- 23. M. Yang, A. Ye, Z. Yang, D. W. Everett, E. P. Gilbert and H. Singh, Food & Function, 2023.
- 24. H. M. Farrell, E. L. Malin, E. M. Brown and P. X. Qi, *Current Opinion in Colloid & Interface Science*, 2006, **11**, 135-147.
- 25. J. Zhang, D. Liu, Y. Xie, J. Yuan, K. Wang, X. Tao, Y. Hemar, J. M. Regenstein, X. Liu and P. Zhou, *Food Chemistry*, 2023, **416**, 135865.
- 26. T. Huppertz and T. T. Lambers, International Dairy Journal, 2020, 107, 104717.
- 27. K. Wang, D. Liu, X. Tao, J. Zhang, T. Huppertz, J. M. Regenstein, X. Liu and P. Zhou, *Food Hydrocolloids*, 2023, **139**, 108515.
- 28. R. Spiller and L. Marciani, *Nutrients*, 2019, **11**.
- 29. P. A. M. Smeets, R. Deng, E. J. M. van Eijnatten and M. Mayar, *The Proceedings of the Nutrition Society*, 2020, DOI: 10.1017/s0029665120007867, 1-11.
- 30. G. Camps, M. Mars, C. de Graaf and P. A. M. Smeets, *Physiology & Behavior*, 2017, **176**, 26-30.
- 31. Marciani, N. Hall, S. E. Pritchard, E. F. Cox, J. J. Totman, M. Lad, C. L. Hoad, T. J. Foster, P. A. Gowland and R. C. Spiller, *The Journal of Nutrition*, 2012, **142**, 1253-1258.
- 32. M. Coletta, F. K. Gates, L. Marciani, H. Shiwani, G. Major, C. L. Hoad, G. Chaddock, P. A. Gowland and R. C. Spiller, *The British journal of nutrition*, 2016, **115**, 55-61.
- 33. O. P. Soldin and D. R. Mattison, *Clinical Pharmacokinetics*, 2009, **48**, 143-157.
- 34. C. Lajterer, C. Shani Levi and U. Lesmes, *Food Hydrocolloids*, 2022, **132**, 107850.
- 35. J. Blundell, C. de Graaf, T. Hulshof, S. Jebb, B. Livingstone, A. Lluch, D. Mela, S. Salah, E. Schuring, H. van der Knaap and M. Westerterp, *Obes Rev*, 2010, **11**, 251-270.
- 36. T. Huppertz and C. Timmer, *International Dairy Journal*, 2020, **110**, 104805.
- H. Priyashantha, Å. Lundh, A. Höjer, M. Hetta, M. Johansson and M. Langton, J Texture Stud, 2019, 50, 508-519.
- 38. M. J. McAuliffe, F. M. Lalonde, D. McGarry, W. Gandler, K. Csaky and B. L. Trus, 2001.
- 39. C. Nioche, F. Orlhac, S. Boughdad, S. Reuzé, J. Goya-Outi, C. Robert, C. Pellot-Barakat, M. Soussan, F. Frouin and I. Buvat, *Cancer Research*, 2018, **78**, 4786.

#### It is made available under a CC-BY-ND 4.0 International license .

- 40. R. Thomas, L. Qin, F. Alessandrino, S. P. Sahu, P. J. Guerra, K. M. Krajewski and A. Shinagare, *Abdom Radiol (NY)*, 2019, **44**, 2501-2510.
- 41. N. Otsu, *IEEE Transactions on Systems, Man, and Cybernetics*, 1979, **9**, 62-66.
- 42. M. Mayar, P. Smeets, J. van Duynhoven and C. Terenzi, *Food Structure*, 2023, **36**, 100314.
- 43. G. Hermann, M. Schwaiger, P. Volejnik and G. Koellensperger, *Journal of Pharmaceutical and Biomedical Analysis*, 2018, **155**, 329-334.
- 44. G. Camps, M. Mars, B. J. M. Witteman, C. de Graaf and P. A. M. Smeets, *Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society*, 2018, DOI: 10.1111/nmo.13317.
- 45. H. Fruehauf, D. Menne, M. A. Kwiatek, Z. Forras-Kaufman, E. Kaufman, O. Goetze, M. Fried, W. Schwizer and M. Fox, *Neurogastroenterol. Motil.*, 2011, **23**, 854-861.
- 46. R development Core Team, *Journal*, 2017.
- 47. W. Jacobs, P. Johns, P. Haselberger, J. J. Thompson, D. Sullivan and S. Baugh, *Journal of AOAC INTERNATIONAL*, 2019, **96**, 502-507.
- 48. J. Gao, X. Huang, H. Meng, M. Zhang, X. Zhang, X. Lin and B. Li, *Frontiers in oncology*, 2020, **10**, 198.
- 49. Q. N. Do, M. A. Lewis, A. J. Madhuranthakam, Y. Xi, A. A. Bailey, R. E. Lenkinski and D. M. Twickler, *PloS* one, 2019, **14**, e0211060-e0211060.
- 50. X. Wang, A. Ye, Q. Lin, J. Han and H. Singh, *Journal of Dairy Science*, 2018, **101**, 6842-6852.
- 51. R. Deng, A. Seimys, M. Mars, A. E. M. Janssen and P. A. M. Smeets, *Food Hydrocolloids*, 2022, **125**, 107393.
- 52. R. Deng, M. Mars, A. E. M. Janssen and P. A. M. Smeets, Food Hydrocolloids, 2023, 141, 108689.
- 53. A. Ye, J. Cui, D. Dalgleish and H. Singh, *Food & Function*, 2016, **7**, 4259-4266.
- 54. S. Kuyumcu, D. Menne, J. Curcic, O. Goetze, M. Klebach, E. Abrahamse, Z. Hofman, M. Fried, W. Schwizer and A. Steingoetter, *JPEN J Parenter Enteral Nutr*, 2015, **39**, 544-551.
- 55. A. C. Brun, K. Størdal, G. B. Johannesdottir, B. S. Bentsen and A. W. Medhus, *Clin Nutr*, 2012, **31**, 108-112.
- 56. T. Thorkelsson, F. Mimouni, R. Namgung, M. Fernández-Ulloa, S. Krug-Wispé and R. C. Tsang, *Pediatric research*, 1994, **36**, 329-333.
- 57. A. H. Chan, R. F. D'Souza, J. W. Beals, N. Zeng, U. Prodhan, A. C. Fanning, S. D. Poppitt, Z. Li, N. A. Burd, D. Cameron-Smith and C. J. Mitchell, *The Journal of Nutrition*, 2019, **149**, 1511-1522.
- S. S. Fajans, J. C. Floyd, R. F. Knopf and J. W. Conn, in *Schering Symposium on Endocrinology, Berlin, May 26 to 27, 1967*, ed. G. Raspé, Pergamon, 1969, DOI: <u>https://doi.org/10.1016/B978-0-08-013395-9.50021-6</u>, pp. 231-238.
- 59. B. v. Sloun, G. H. Goossens, B. Erdos, M. Lenz, N. v. Riel and I. C. W. Arts, *Nutrients*, 2020, **12**, 3211.

2

# **LEGENDS FOR FIGURES**

## Figure 1. Overview of a test session

Figure 2. Mean ± SEM of image texture metric homogeneity of gastric content as visible on MRI after low and high CM milk ingestion. \*p < 0.05 placed above the value denotes a significant time point, at the right of the graph it denotes a significant treatment effect.</li>
A difference in image texture metrics may reflect a difference in casein coagulation.
Figure 3. Mean ± SEM gastric content over time after ingestion of 600 ml of low and high CM milk. There were no significant differences between the two treatments.

**Figure 4.** Mean  $\pm$  SEM of serum essential amino acid (A), non-essential amino acid (B), branch chained amino acids (C) and valine (D) concentrations after low and high CM milk ingestion. \*p < 0.05 placed above the value denotes a significant time point, at the right of the graph it denotes a significant treatment effect.

**Figure 5.** Estimated serum whey/casein AA ratio over time after low and high CM milk ingestion. \*p < 0.05 placed above the value denotes a significant time point, at the right of the graph it denotes a significant treatment effect.

**Figure 6.** Mean  $\pm$  SEM plasma glucose (mmol/L) and serum insulin (mIU/L) concentrations over time after low and high CM milk ingestion. \*p < 0.05 placed above the value denotes a significant time point, at the right of the graph it denotes a significant treatment effect.











